| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome.
|
Science
|
1989
|
37.89
|
|
2
|
Global epidemiology of hepatitis C virus infection.
|
Lancet Infect Dis
|
2005
|
16.44
|
|
3
|
Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus.
|
Hepatology
|
2015
|
6.73
|
|
4
|
Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression.
|
Gastroenterology
|
2009
|
5.87
|
|
5
|
Hepatitis C virus infection in USA: an estimate of true prevalence.
|
Liver Int
|
2011
|
3.36
|
|
6
|
KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease.
|
Kidney Int Suppl
|
2008
|
3.00
|
|
7
|
Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study.
|
Lancet
|
2015
|
2.91
|
|
8
|
Estimating progression to cirrhosis in chronic hepatitis C virus infection.
|
Hepatology
|
2001
|
2.90
|
|
9
|
Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial.
|
Ann Intern Med
|
2015
|
2.13
|
|
10
|
National surveillance of dialysis-associated diseases in the United States, 2002.
|
Semin Dial
|
2005
|
1.75
|
|
11
|
A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin.
|
Gastroenterology
|
2010
|
1.70
|
|
12
|
Genetic diversity of recently acquired and prevalent HIV, hepatitis B virus, and hepatitis C virus infections in US blood donors.
|
J Infect Dis
|
2012
|
1.43
|
|
13
|
Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent.
|
J Hepatol
|
2015
|
1.28
|
|
14
|
Barriers to hepatitis C treatment.
|
Liver Int
|
2012
|
1.13
|
|
15
|
Hepatitis C Treatment and Barriers to Eradication.
|
Clin Transl Gastroenterol
|
2016
|
0.75
|